AZ Crows About Oncology Portfolio In 1Q; Strives For $1.1bn Cost Save
Executive Summary
AstraZeneca PLC is restructuring and streamlining its commercial and manufacturing operations under a new cost-cutting effort in order to save $1.1bn annually from 2017 and focus internally on just three core areas.
You may also be interested in...
Generic Crestor Marks The End Of An Era, Should Quickly Outperform PCSK9s
The launch of generic rosuvastatin offers yet another way to calculate the disappointing performance of the PCSK9 inhibitors.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.